Business
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients.
About this update from Volitionrx Limited
[{"type":"text","content":"HENDERSON, Nev.,, December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients.","length":375,"tagName":"p"},{"type":"text","content":"Prognostic Value of Circulating H3K27Me3-Nucleosomes in Newly Diagnosed Lung Cancer Patients","length":92,"tagName":"p"},{"type":"text","content":"Professor Lea Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon and Hospices Civils de Lyon, France, said:","length":139,"tagName":"p"},{"type":"text","content":""This large-scale study demonstrates that Nu.Q®-H3K27Me3 levels increase with cancer disease stages and importantly, that their level at diagnosis emerges as an independent prognostic biomarker for overall survival. It offers a practical approach to refine risk assessment, particularly within the ctDNA-negative subgroup and to inform clinical decision-making in the context of personalized therapeutic strategies.","length":420,"tagName":"p"},{"type":"text","content":""We have worked closely with the Volition team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q® in the management of cancer patients.","length":191,"tagName":"p"},{"type":"text","content":""We were delighted to place our first order of the Nu.Q® Cancer assays recently so we might complete the internal certification process ahead of introducing the test into routine clinical practice in our hospital network for cancer management."","length":254,"tagName":"p"},{"type":"text","content":"Pre-operative nucleosome liquid biopsy for risk stratification of lung cancer","length":77,"tagName":"p"},{"type":"text","content":"Joint lead author Dr. Pei-Hsing Chen, Institute of Biomedical Engineering, National Taiwan University (NTU), Taipei City, Taiwan, said: "A key finding from this study was that measuring preoperative H3K27Me3-nucleosomes using Volition's simple blood test allows us to identify which Non Small Cell Lung Cancer patients are most likely to benefit from closer follow-ups or secondary cancer treatment.","length":409,"tagName"...